Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity

Cancer Biol Med. 2023 Oct 9;20(10):728-747. doi: 10.20892/j.issn.2095-3941.2023.0241.

Abstract

Plasmacytoid dendritic cells (pDCs) are a pioneer cell type that produces type I interferon (IFN-I) and promotes antiviral immune responses. However, they are tolerogenic and, when recruited to the tumor microenvironment (TME), play complex roles that have long been a research focus. The interactions between pDCs and other components of the TME, whether direct or indirect, can either promote or hinder tumor development; consequently, pDCs are an intriguing target for therapeutic intervention. This review provides a comprehensive overview of pDC crosstalk in the TME, including crosstalk with various cell types, biochemical factors, and microorganisms. An in-depth understanding of pDC crosstalk in TME should facilitate the development of novel pDC-based therapeutic methods.

Keywords: Plasmacytoid dendritic cell; cell crosstalk; immune activation; immune suppression; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dendritic Cells / metabolism
  • Humans
  • Neoplasms* / metabolism
  • Tumor Microenvironment

Grants and funding

This work was supported by grants from the China Postdoctoral Science Foundation (Grant No. 2022M712880), the Program of the Major Research Plan of the National Natural Science Foundation of China (Grant No. 91942314), and the National Natural Science Foundation of China (Grant No. 82001659).